CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.
IL-21-elicited CD4 T cells enable durable remission in pancreatic cancer by transforming transient KRAS inhibitor responses into long-lasting effects.
- Why it matters: Pancreatic ductal adenocarcinoma (PDAC) is resistant to most treatments, including immunotherapies, and resistance to KRAS inhibitors limits their long-term success, highlighting the need for strategies that sustain remission.
- What they did: The study used mouse models to test IL-21 mimics, finding that their effectiveness depends on Th1-polarized CD4 T cells, which produce IFN-γ and promote macrophage-mediated tumor cell destruction, independent of CD8 T cells or MHC class I.
- The result: This approach induces durable tumor remissions and suggests that activating CD4 T cells with IL-21 could improve outcomes in human PDAC, converting short-term responses into lasting cures.